Were any cash payments involved in the LeMaitre Vascular (LMAT) insider share acquisitions?

The reported common stock acquisitions occurred at a price of $0 per share, with the filing noting that any fractional shares from dividend equivalent rights were settled in cash.

LeMaitre Vascular director reports stock from dividend equivalents

Q: What insider transaction did LeMaitre Vascular (LMAT) report in this filing?

The filing reports a director acquiring LeMaitre Vascular common stock through the release of dividend equivalent rights on 12/11/2025 and 12/12/2025.

Q: How many LeMaitre Vascular (LMAT) shares did the director acquire?

The director acquired 25, 18, and 18 shares of common stock, all at a price of $0 per share, as the dividend equivalent rights vested.

Q: What is the director's share ownership in LeMaitre Vascular (LMAT) after these transactions?

Following the reported transactions, the director directly beneficially owned 10,183 shares of LeMaitre Vascular common stock.

Q: What are dividend equivalent rights in this LeMaitre Vascular (LMAT) filing?

Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and converts into shares when related stock awards vest.

LeMaitre Vascular, Inc. director filed a report of routine equity-related transactions.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

LeMaitre Vascular, Inc. director filed a report of routine equity-related transactions. On 12/11/2025 and 12/12/2025, the director acquired 25, 18, and 18 shares of common stock at a price of $0 per share following the release of dividend equivalent rights tied to prior stock awards. After these transactions, the director directly beneficially owned 10,183 shares of common stock.

The filing shows dividend equivalent rights converting into common stock on a one-for-one basis, connected to restricted stock unit and performance stock unit awards granted in 2021 and 2022. Fractional shares from these rights, if any, were settled in cash, leaving derivative right balances such as 19.974 and 19.291 units outstanding.

Insider Trade Summary

61 shares exercised/converted

Exercise 6 txns

Insider Pellegrino Joseph P JR

Role Director

Type	Security	Shares	Price	Value
Exercise	Dividend Equivalent Rights	18	$0.00	$0.00
Exercise	Dividend Equivalent Rights	18	$0.00	$0.00
Exercise	Common Stock	18	$0.00	$0.00
Exercise	Common Stock	18	$0.00	$0.00
Exercise	Dividend Equivalent Rights	25	$0.00	$0.00
Exercise	Common Stock	25	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 39.265 contracts (Direct); Common Stock — 10,183 shares (Direct)

Footnotes (5)

F1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
F2. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/11/2021. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F3. Fractional shares released (if any) on each vesting date were settled in cash, resulting in a final balance of zero.
F4. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F5. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LeMaitre Vascular (LMAT) report in this filing?

The filing reports a director acquiring LeMaitre Vascular common stock through the release of dividend equivalent rights on 12/11/2025 and 12/12/2025.

How many LeMaitre Vascular (LMAT) shares did the director acquire?

The director acquired 25, 18, and 18 shares of common stock, all at a price of $0 per share, as the dividend equivalent rights vested.

What are dividend equivalent rights in this LeMaitre Vascular (LMAT) filing?

Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and converts into shares when related stock awards vest.

Which stock awards triggered the dividend equivalent rights in this LMAT insider report?

The dividend equivalent rights were released in connection with the vesting of restricted stock unit and performance stock unit awards granted on 12/11/2021 and 12/12/2022.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 12/15/2025 - 06:12 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pellegrino Joseph P JR

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

01803

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	12/11/2025		M		25⁽¹⁾	A	$0⁽¹⁾	10,147	D
Common Stock	12/12/2025		M		18⁽¹⁾	A	$0⁽¹⁾	10,165	D
Common Stock	12/12/2025		M		18⁽¹⁾	A	$0⁽¹⁾	10,183	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Dividend Equivalent Rights	⁽²⁾	12/11/2025		M			25⁽²⁾	⁽²⁾	⁽²⁾	Common Stock	25	$0	0⁽³⁾	D
Dividend Equivalent Rights	⁽⁴⁾	12/12/2025		M			18⁽⁴⁾	⁽⁴⁾	⁽⁴⁾	Common Stock	18	$0	19.974	D
Dividend Equivalent Rights	⁽⁵⁾	12/12/2025		M			18⁽⁵⁾	⁽⁵⁾	⁽⁵⁾	Common Stock	18	$0	19.291	D

Explanation of Responses:

1. Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.

2. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/11/2021. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. Fractional shares released (if any) on each vesting date were settled in cash, resulting in a final balance of zero.

4. These dividend equivalent rights were released in connection with the vesting of a restricted stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights were released in connection with the vesting of a performance stock unit award granted on 12/12/2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR